Table 3. Biological validation in tissues from U.S. and S. Korea patient cohorts.

Metrics are shown for discrimination of gastric adenocarcinoma from histologically normal gastric mucosa by the top 16 methylated DNA markers, including areas under the receiver operator curves (AUCs) and sensitivites at 90% specificity cuttoffs. Specificity cutoffs were based on marker levels in histologically normal mucosa from healthy controls in U.S. cohort and from biopsies synchronous with gastric cancer in S. Korea cohort.

	U.S. Cohort		South Korea Cohort
	AUC (95% CI)	Sensitivity, % (95% CI)	AUC (95% CI)	Sensitivity, % (95% CI)
ARGEF4	0.97 (0.93–1)	94 (81–99)	0.82 (0.72–0.92)	72 (58–84)
ELMO1	0.97 (0.93–1)	94 (81–99)	0.92 (0.86–0.99)	88 (76–95)
ABCB1	0.98 (0.96–1)	91 (77–98)	0.83 (0.74–0.92)	78 (64–88)
BMP3	0.94 (0.88–1)	89 (73–97)	0.84 (0.75–0.94)	80 (66–90)
SP9	0.95 (0.91–1)	91 (77–98)	0.66 (0.53–0.79)	58 (43–72)
CLEC11A	0.95 (0.92–1)	94 (81–99)	0.78 (0.66–0.89)	68 (53–80)
EMX1	0.96 (0.91–1)	91 (77–98)	0.77 (0.65–0.89)	76 (62–87)
ST8SIA1	0.95 (0.89–1)	91 (77–98)	0.85 (0.76–0.93)	72 (58–84)
CD1D	0.94 (0.88–0.99)	89 (73–97)	0.91 (0.84–0.98)	86 (73–94)
SFMBT2	0.93 (0.87–0.99)	86 (70–95)	0.96 (0.92–1)	90 (78–97)
CYP26C1	0.95 (0.89–1)	91 (77–98)	0.84 (0.74–0.93)	74 (60–85)
PKIA	0.94 (0.89–1)	89 (73–97)	0.89 (0.82–0.97)	80 (66–90)
NDRG4	0.88 (0.81–0.96)	77 (60–90)	0.84 (0.77–0.92)	74 (60–85)
ZNF569	0.94 (0.88–1)	91 (77–98)	0.81 (0.70–0.91)	70 (55–82)
PPP2R5C	0.90 (0.83–0.97)	80 (63–92)	0.68 (0.56–0.80)	62 (47–75)
C13ORF18	0.83 (0.72–0.93)	74 (57–88)	0.85 (0.78–0.92)	72 (58–84)
Marker Panel	0.99 (0.96–1)	100 (90–100)	0.95 (0.89–1)	94 (83–99)